Both in Biotechnology
REGENXBIO vs Editas Medicine
Over the past year RGNX returned −43.6% and EDIT returned −13.3%; their daily moves had a correlation of 0.46.
RGNX −43.6% EDIT −13.3%Growth of $1, one year, split-adjusted
| Metric | RGNX | EDIT |
|---|---|---|
| Price | $7.20 | $2.67 |
| Market cap | $475.3M | $410.1M |
| Today | −2.83% | −8.87% |
| 1 month | −3.0% | +6.0% |
| 6 months | −21.1% | −7.9% |
| Year to date | −50.0% | +30.2% |
| 1 year | −43.9% | −12.2% |
| Revenue growth (YoY) | +405.7% | +232.3% |
| Gross margin | 99.0% | 100.0% |
| Net margin | 21.0% | −153.3% |
| P/E (TTM) | — | — |
| Price / sales | 2.7× | 8.7× |
| Net cash | $105.5M | $155.9M |
| Dividend yield | — | — |
| Volatility (60d) | 86.5% | 81.4% |
| Short % of float | 19.4% | 25.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).